Gene: ARHGEF7
Official Full Name: Rho guanine nucleotide exchange factor 7provided by HGNC
Gene Summary: This gene encodes a protein that belongs to a family of cytoplasmic proteins that activate the Ras-like family of Rho proteins by exchanging bound GDP for GTP. It forms a complex with the small GTP binding protein Rac1 and recruits Rac1 to membrane ruffles and to focal adhesions. Multiple alternatively spliced transcript variants encoding different isoforms have been observed for this gene. [provided by RefSeq, Mar 2016]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO33767 | ARHGEF7 Knockout cell line (HeLa) | Human | ARHGEF7 | 1:3~1:6 | Negative | Online Inquiry |
KO33768 | ARHGEF7 Knockout cell line (HCT 116) | Human | ARHGEF7 | 1:2~1:4 | Negative | Online Inquiry |
KO33769 | ARHGEF7 Knockout cell line (HEK293) | Human | ARHGEF7 | 1:3~1:6 | Negative | Online Inquiry |
ARHGEF7 Gene Knockout Cell Lines are specialized cellular models that have undergone targeted gene editing to inactivate the ARHGEF7 gene, which is known for its crucial role in regulating Rho GTPases involved in various cellular functions such as proliferation, migration, and adhesion. These cell lines provide valuable tools for investigating the physiological and pathological roles of ARHGEF7, allowing researchers to study its impact on cellular signaling pathways and disease mechanisms.
These knockout cell lines are engineered using advanced CRISPR/Cas9 technology, ensuring specific and efficient gene disruption. By removing the ARHGEF7 expression, researchers can study the resultant effects on cytoskeletal organization and cell behavior in a controlled environment. This is particularly significant in cancer research, where altered Rho signaling is frequently implicated in tumor progression and metastasis.
In clinical settings, ARHGEF7 knockouts can facilitate drug development by providing insights into how modulation of Rho GTPase activity may lead to therapeutic effects. Moreover, they are invaluable for studying neurological disorders, cardiovascular diseases, and immune responses, given the gene's involvement in various signaling cascades.
Compared to conventional methods, the use of ARHGEF7 Gene Knockout Cell Lines presents distinct advantages, such as reproducibility, specificity, and the ability to perform high-throughput screening. This makes them superior alternatives for gene function studies over wild-type cell lines, which may confound results due to off-target effects or variable expression levels.
For researchers and clinicians looking to deepen their understanding of Rho GTPase pathways and leverage those insights for innovative therapies, ARHGEF7 Gene Knockout Cell Lines represent a robust, scientifically grounded resource. Our company specializes in the development and production of high-quality biological products, ensuring that scientists have access to the tools necessary to advance their research successfully and effectively.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.